{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000146","form_type":"8-K","ticker":"TLRY","cik":"0001731348","company_name":"Tilray Brands, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.026064+00:00","generated_at":"2026-05-16T11:13:54.138220+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Tilray Brands Q2 FY2026 revenue record $218M; net cash $30M; reaffirms EBITDA guidance","bullets":["Net revenue $218M, a record quarterly; international medical cannabis revenue increased 36% YoY.","Ended quarter with $292M cash and marketable securities; net cash position of approximately $30M.","Canadian adult-use cannabis revenue grew 6% YoY; Tilray Pharma achieved record quarterly revenue.","Reaffirmed full-year adjusted EBITDA guidance; Chairman cites disciplined execution and long-term value.","U.S. federal cannabis rescheduling expected to unlock new market opportunity for Tilray Medical expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000146","json":"https://secwatch.observer/filing/0001171843-26-000146.json","markdown":"https://secwatch.observer/filing/0001171843-26-000146.md","text":"https://secwatch.observer/filing/0001171843-26-000146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1731348/000117184326000146/0001171843-26-000146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1731348/000117184326000146/f8k_010826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:13:54.138220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}